Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study

The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using...

Full description

Saved in:
Bibliographic Details
Published in:Future science OA 2021-04, Vol.7 (4), p.FSO673
Main Authors: Cerino, Pellegrino, Coppola, Annachiara, Volzone, Palmiero, Pizzolante, Antonio, Pierri, Biancamaria, Atripaldi, Luigi, Zollo, Massimo, Capasso, Mario, Ascierto, Paolo Antonio, Triassi, Maria, Brambilla, Gianfranco, Perrella, Alessandro, Bruzzese, Dario, Buonerba, Carlo
Format: Article
Language:English
Subjects:
Ariano Irpino
COVID-19
epidemiology
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143
cites cdi_FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143
container_end_page
container_issue 4
container_start_page FSO673
container_title Future science OA
container_volume 7
creator Cerino, Pellegrino
Coppola, Annachiara
Volzone, Palmiero
Pizzolante, Antonio
Pierri, Biancamaria
Atripaldi, Luigi
Zollo, Massimo
Capasso, Mario
Ascierto, Paolo Antonio
Triassi, Maria
Brambilla, Gianfranco
Perrella, Alessandro
Bruzzese, Dario
Buonerba, Carlo
description The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using the Roche Cobas Elecsys anti-SARS-CoV-2 assay was organized by the Zoo-Prophylactic Institute of Southern Italy (Portici, Italy) and conducted in cooperation with the Local Health Unit (Azienda Sanitaria Locale - ASL - Avellino, Avellino, Italy), the Department of Public Health of University Federico II (Naples, Italy) and Department of Health Services of Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital (Naples, Italy) in May 2020. A total of 13,218 asymptomatic individuals were reviewed in this analysis. A total of 738 citizens tested positive for anti-SARS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6% (95% CI: 5.2-6.0). Among seropositive citizens, 101 cases tested positive on RT-PCR (0.76% of the overall population). Among citizens aged 14-18, 18-65 and >65 years, the seroprevalence was equal to 6.1 (95% CI: 4.1-8.7), 5.6 (95% CI: 5.1-6.1) and 4% (95% CI: 3.3-4.8), respectively. In the pediatric cohort (
doi_str_mv 10.2144/fsoa-2020-0203
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e8c93165cedb4ce898b3e2919cc7fe75</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e8c93165cedb4ce898b3e2919cc7fe75</doaj_id><sourcerecordid>2508889995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143</originalsourceid><addsrcrecordid>eNpVkk1r3DAQhk1paUKaa49FxxSiVJ-21ENhWfqxECh0217FWB4nCl7Llewte-4fr91NQ3IQMxq9emaQ3qJ4zdmV4Eq9a3MEKphgdF7yWXEqmC6pLoV8_ig_Kc5zvmOM8XlXCvOyOJHScG24PS3-bDHFIeEeOuw9ktiS7erblq7jTypoHtCHNngC_Rjq2ATMJPRkvEUyxt_9ol6lAH0kmzSEOVys9th1c3ZJ1rAboA9wSTYjdIe37wmQIQ5TB2OIPa0hY0PyODWHV8WLFrqM5_fxrPjx6eP39Rd6_fXzZr26pl7pcqQVgLCVbKTiTFghLChVai1rUSpEkJUsOaK1qvSaN0bzykvQUtfWqJZzJc-KzZHbRLhzQwo7SAcXIbh_hZhuHKQx-A4dGm8lL7XHplYejTW1RGG59b5qsdIz68ORNUz1DhuP_ZigewJ9etKHW3cT964yTCjJZ8DFPSDFXxPm0e1C9vPjQY9xyk5oZoyx1i69ro5Sn2LOCduHNpy5xQhuMYJbjOAWI8wX3jwe7kH-_9vlX1TDrog</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2508889995</pqid></control><display><type>article</type><title>Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study</title><source>NCBI_PubMed Central（免费）</source><creator>Cerino, Pellegrino ; Coppola, Annachiara ; Volzone, Palmiero ; Pizzolante, Antonio ; Pierri, Biancamaria ; Atripaldi, Luigi ; Zollo, Massimo ; Capasso, Mario ; Ascierto, Paolo Antonio ; Triassi, Maria ; Brambilla, Gianfranco ; Perrella, Alessandro ; Bruzzese, Dario ; Buonerba, Carlo</creator><creatorcontrib>Cerino, Pellegrino ; Coppola, Annachiara ; Volzone, Palmiero ; Pizzolante, Antonio ; Pierri, Biancamaria ; Atripaldi, Luigi ; Zollo, Massimo ; Capasso, Mario ; Ascierto, Paolo Antonio ; Triassi, Maria ; Brambilla, Gianfranco ; Perrella, Alessandro ; Bruzzese, Dario ; Buonerba, Carlo</creatorcontrib><description>The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using the Roche Cobas Elecsys anti-SARS-CoV-2 assay was organized by the Zoo-Prophylactic Institute of Southern Italy (Portici, Italy) and conducted in cooperation with the Local Health Unit (Azienda Sanitaria Locale - ASL - Avellino, Avellino, Italy), the Department of Public Health of University Federico II (Naples, Italy) and Department of Health Services of Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital (Naples, Italy) in May 2020. A total of 13,218 asymptomatic individuals were reviewed in this analysis. A total of 738 citizens tested positive for anti-SARS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6% (95% CI: 5.2-6.0). Among seropositive citizens, 101 cases tested positive on RT-PCR (0.76% of the overall population). Among citizens aged 14-18, 18-65 and &gt;65 years, the seroprevalence was equal to 6.1 (95% CI: 4.1-8.7), 5.6 (95% CI: 5.1-6.1) and 4% (95% CI: 3.3-4.8), respectively. In the pediatric cohort (&lt;14 years old), seroprevalence was 13% (95% CI: 10.2-16.2). A serological-based screening strategy could be a cost-effective public health intervention to tackle the COVID-19 pandemic.</description><identifier>ISSN: 2056-5623</identifier><identifier>EISSN: 2056-5623</identifier><identifier>DOI: 10.2144/fsoa-2020-0203</identifier><identifier>PMID: 33815819</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Ariano Irpino ; COVID-19 ; epidemiology ; SARS-CoV-2</subject><ispartof>Future science OA, 2021-04, Vol.7 (4), p.FSO673</ispartof><rights>2021 Carlo Buonerba.</rights><rights>2021 Carlo Buonerba. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143</citedby><cites>FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802431/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802431/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33815819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cerino, Pellegrino</creatorcontrib><creatorcontrib>Coppola, Annachiara</creatorcontrib><creatorcontrib>Volzone, Palmiero</creatorcontrib><creatorcontrib>Pizzolante, Antonio</creatorcontrib><creatorcontrib>Pierri, Biancamaria</creatorcontrib><creatorcontrib>Atripaldi, Luigi</creatorcontrib><creatorcontrib>Zollo, Massimo</creatorcontrib><creatorcontrib>Capasso, Mario</creatorcontrib><creatorcontrib>Ascierto, Paolo Antonio</creatorcontrib><creatorcontrib>Triassi, Maria</creatorcontrib><creatorcontrib>Brambilla, Gianfranco</creatorcontrib><creatorcontrib>Perrella, Alessandro</creatorcontrib><creatorcontrib>Bruzzese, Dario</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><title>Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study</title><title>Future science OA</title><addtitle>Future Sci OA</addtitle><description>The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using the Roche Cobas Elecsys anti-SARS-CoV-2 assay was organized by the Zoo-Prophylactic Institute of Southern Italy (Portici, Italy) and conducted in cooperation with the Local Health Unit (Azienda Sanitaria Locale - ASL - Avellino, Avellino, Italy), the Department of Public Health of University Federico II (Naples, Italy) and Department of Health Services of Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital (Naples, Italy) in May 2020. A total of 13,218 asymptomatic individuals were reviewed in this analysis. A total of 738 citizens tested positive for anti-SARS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6% (95% CI: 5.2-6.0). Among seropositive citizens, 101 cases tested positive on RT-PCR (0.76% of the overall population). Among citizens aged 14-18, 18-65 and &gt;65 years, the seroprevalence was equal to 6.1 (95% CI: 4.1-8.7), 5.6 (95% CI: 5.1-6.1) and 4% (95% CI: 3.3-4.8), respectively. In the pediatric cohort (&lt;14 years old), seroprevalence was 13% (95% CI: 10.2-16.2). A serological-based screening strategy could be a cost-effective public health intervention to tackle the COVID-19 pandemic.</description><subject>Ariano Irpino</subject><subject>COVID-19</subject><subject>epidemiology</subject><subject>SARS-CoV-2</subject><issn>2056-5623</issn><issn>2056-5623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1r3DAQhk1paUKaa49FxxSiVJ-21ENhWfqxECh0217FWB4nCl7Llewte-4fr91NQ3IQMxq9emaQ3qJ4zdmV4Eq9a3MEKphgdF7yWXEqmC6pLoV8_ig_Kc5zvmOM8XlXCvOyOJHScG24PS3-bDHFIeEeOuw9ktiS7erblq7jTypoHtCHNngC_Rjq2ATMJPRkvEUyxt_9ol6lAH0kmzSEOVys9th1c3ZJ1rAboA9wSTYjdIe37wmQIQ5TB2OIPa0hY0PyODWHV8WLFrqM5_fxrPjx6eP39Rd6_fXzZr26pl7pcqQVgLCVbKTiTFghLChVai1rUSpEkJUsOaK1qvSaN0bzykvQUtfWqJZzJc-KzZHbRLhzQwo7SAcXIbh_hZhuHKQx-A4dGm8lL7XHplYejTW1RGG59b5qsdIz68ORNUz1DhuP_ZigewJ9etKHW3cT964yTCjJZ8DFPSDFXxPm0e1C9vPjQY9xyk5oZoyx1i69ro5Sn2LOCduHNpy5xQhuMYJbjOAWI8wX3jwe7kH-_9vlX1TDrog</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Cerino, Pellegrino</creator><creator>Coppola, Annachiara</creator><creator>Volzone, Palmiero</creator><creator>Pizzolante, Antonio</creator><creator>Pierri, Biancamaria</creator><creator>Atripaldi, Luigi</creator><creator>Zollo, Massimo</creator><creator>Capasso, Mario</creator><creator>Ascierto, Paolo Antonio</creator><creator>Triassi, Maria</creator><creator>Brambilla, Gianfranco</creator><creator>Perrella, Alessandro</creator><creator>Bruzzese, Dario</creator><creator>Buonerba, Carlo</creator><general>Future Science Ltd</general><general>Taylor &amp; Francis Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210401</creationdate><title>Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study</title><author>Cerino, Pellegrino ; Coppola, Annachiara ; Volzone, Palmiero ; Pizzolante, Antonio ; Pierri, Biancamaria ; Atripaldi, Luigi ; Zollo, Massimo ; Capasso, Mario ; Ascierto, Paolo Antonio ; Triassi, Maria ; Brambilla, Gianfranco ; Perrella, Alessandro ; Bruzzese, Dario ; Buonerba, Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ariano Irpino</topic><topic>COVID-19</topic><topic>epidemiology</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cerino, Pellegrino</creatorcontrib><creatorcontrib>Coppola, Annachiara</creatorcontrib><creatorcontrib>Volzone, Palmiero</creatorcontrib><creatorcontrib>Pizzolante, Antonio</creatorcontrib><creatorcontrib>Pierri, Biancamaria</creatorcontrib><creatorcontrib>Atripaldi, Luigi</creatorcontrib><creatorcontrib>Zollo, Massimo</creatorcontrib><creatorcontrib>Capasso, Mario</creatorcontrib><creatorcontrib>Ascierto, Paolo Antonio</creatorcontrib><creatorcontrib>Triassi, Maria</creatorcontrib><creatorcontrib>Brambilla, Gianfranco</creatorcontrib><creatorcontrib>Perrella, Alessandro</creatorcontrib><creatorcontrib>Bruzzese, Dario</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Future science OA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cerino, Pellegrino</au><au>Coppola, Annachiara</au><au>Volzone, Palmiero</au><au>Pizzolante, Antonio</au><au>Pierri, Biancamaria</au><au>Atripaldi, Luigi</au><au>Zollo, Massimo</au><au>Capasso, Mario</au><au>Ascierto, Paolo Antonio</au><au>Triassi, Maria</au><au>Brambilla, Gianfranco</au><au>Perrella, Alessandro</au><au>Bruzzese, Dario</au><au>Buonerba, Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study</atitle><jtitle>Future science OA</jtitle><addtitle>Future Sci OA</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>7</volume><issue>4</issue><spage>FSO673</spage><pages>FSO673-</pages><issn>2056-5623</issn><eissn>2056-5623</eissn><abstract>The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using the Roche Cobas Elecsys anti-SARS-CoV-2 assay was organized by the Zoo-Prophylactic Institute of Southern Italy (Portici, Italy) and conducted in cooperation with the Local Health Unit (Azienda Sanitaria Locale - ASL - Avellino, Avellino, Italy), the Department of Public Health of University Federico II (Naples, Italy) and Department of Health Services of Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital (Naples, Italy) in May 2020. A total of 13,218 asymptomatic individuals were reviewed in this analysis. A total of 738 citizens tested positive for anti-SARS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6% (95% CI: 5.2-6.0). Among seropositive citizens, 101 cases tested positive on RT-PCR (0.76% of the overall population). Among citizens aged 14-18, 18-65 and &gt;65 years, the seroprevalence was equal to 6.1 (95% CI: 4.1-8.7), 5.6 (95% CI: 5.1-6.1) and 4% (95% CI: 3.3-4.8), respectively. In the pediatric cohort (&lt;14 years old), seroprevalence was 13% (95% CI: 10.2-16.2). A serological-based screening strategy could be a cost-effective public health intervention to tackle the COVID-19 pandemic.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>33815819</pmid><doi>10.2144/fsoa-2020-0203</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2056-5623
ispartof Future science OA, 2021-04, Vol.7 (4), p.FSO673
issn 2056-5623
2056-5623
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e8c93165cedb4ce898b3e2919cc7fe75
source NCBI_PubMed Central（免费）
subjects Ariano Irpino
COVID-19
epidemiology
SARS-CoV-2
title Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A48%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seroprevalence%20of%20SARS-CoV-2-specific%20antibodies%20in%20the%20town%20of%20Ariano%20Irpino%20(Avellino,%20Campania,%20Italy):%20a%20population-based%20study&rft.jtitle=Future%20science%20OA&rft.au=Cerino,%20Pellegrino&rft.date=2021-04-01&rft.volume=7&rft.issue=4&rft.spage=FSO673&rft.pages=FSO673-&rft.issn=2056-5623&rft.eissn=2056-5623&rft_id=info:doi/10.2144/fsoa-2020-0203&rft_dat=%3Cproquest_doaj_%3E2508889995%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-7aa2973d341029229a446553b264eea37361ee9946c51d8517c3a535b984f1143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2508889995&rft_id=info:pmid/33815819&rfr_iscdi=true